|
|
Thermalin has identified a portfolio of novel heat-stable and fast-acting insulin analogues. The company’s technology is based upon insights into structural factors leading to the irreversible fibrillation and inactivation of insulin in aqueous solution.
Funders:
Grant funding, Angels.
|
|
|